AstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woes
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
By Ben Hirschler
LONDON (Reuters) - AstraZeneca (NYSE: AZN) shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer (NYSE: PFE) in 2014 during the U.S. group's abortive $100 billion attempt to buy the drugmaker.
The British firm's stock has been on a roll recently, helped by a falling pound and speculation that Switzerland's Novartis (NASDAQ: NOVN) might be next to launch a bid. However, the shares were lifted to a high of 55.05 pounds by the misfortunes of Bristol-Myers Squibb (NYSE: BMY).
The failure of Bristol's immunotherapy drug Opdivo to slow disease progression in previously untreated patients with lung cancer as hoped was seen by investors as good news for rivals Merck & Co (NYSE: MRK) and AstraZeneca.
Analysts at Leerink, Jefferies and Deutsche Bank said the negative result with Opdivo increased the potential market opportunity for AstraZeneca's keenly watched combination of durvalumab and tremelimumab.
Crucial clinical trial results with durvalumab, both on its own and in combination with tremelimumab, are due next year.
Chief Executive Pascal Soriot believes AstraZeneca can become a major player in cancer drugs that bolster the immune system. And its ability to carve out billions of dollars in potential sales hinges not only on the effectiveness of its own products but on the competitive profile of rivals.
Cancer is currently the hottest area of research across the drugs industry and some analysts believe this could make AstraZeneca a takeover target once again, with speculation turning last week to Novartis as a bidder.
(Editing by Dale Hudson)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca (AZN) Says FDA Accepts First BLA for Durvalumab in Bladder Cancer with Priority Review
- 21st Century Fox Class A (FOXA) calls active after offer to buy Sky announced
- Bitcoin hits highest levels in almost three years
Create E-mail Alert Related CategoriesReuters, Trader Talk
Related EntitiesDeutsche Bank, Jefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!